ClinicalTrials.gg
RecruitingNCT05627232Updated Mar 12, 2026

Tazemetostat and Palbociclib With CPX-351for R/R AML

A Phase 1 interventional study of Tazemetostat and Liposome-encapsulated Daunorubicin-Cytarabine in Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Thomas Jefferson University · Phase 1, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing CPX-351 in Leukemia, Myeloid, Acute — 15 open to participants now, 23 under way, 4 of them phase 3. CPX-351 · Leukemia, Myeloid, Acute.

Planned enrollment
33rd of 53
24 · median 30
Started
2023
with 4 others
Phase 1
12 of 53
4 open now
Primary completion
2028-01
later than 18 of 22 live
Registered
49th of 53
by date

Among the 53 studies testing CPX-351 in Leukemia, Myeloid, Acute, this one is the 33rd largest by planned enrollment, is one of 5 that started in 2023, is one of 12 in phase 1, reaches primary completion later than 18 of the 22 other live ones, and was the 49th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 53 studies testing CPX-351 in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About CPX-351

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing CPX-351 in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the combination of tazemetostat and CPX-351 (Part 1) and of pre-treatment with palbociclib followed by CPX-351 (Part 2) for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Part 1 of the study will seek to establish the safety, tolerability, biological activity and recommended dose for further evaluation (RDFE) of tazemetostat in combination with standard-dose CPX-351. Part 2 of the study will seek to establish the safety, tolerability, biological activity RDFE of pre-treatment palbociclib prior CPX-351.

Read the detailed description

PRIMARY OBJECTIVE:

Part 1: To determine the RDFE of tazemetostat in combination with CPX-351 in patients with R/R-AML.

Part 2: To determine the RDFE of palbociclib pre-treatment prior to CPX-351 in patients with R/R-AML.

SECONDARY OBJECTIVE:

I. To evaluate the preliminary efficacy of tazemetostat in combination with CPX-351 (Part 1) and of palbociclib pre-treatment followed by CPX-351 (Part 2).

EXPLORATORY OBJECTIVES:

  1. To determine whether treatment with the EZH2 inhibitor tazemetostat de-condenses the H3K27me3-marked chromatin of AML blasts.
  2. To determine whether cell cycle re-entry of AML cells after palbociclib treatment influences DNA damage and apoptosis induced by combining EZH2 inhibition with anthracycline-based therapy

This is a phase 1b, single-institution, two-part, dose-escalation study utilizing tazemetostat in combination with CPX-351 (Part 1) and palbociclib pre-treatment followed by CPX-351 (Part 2) for patients with R/R-AML who are fit to receive intensive chemotherapy. The study will take place in two parts:

Part 1: Dose escalation via traditional 3+3 design of tazemetostat in combination with CPX-351 .

Part 2: Dose escalation via traditional 3+3 design of palbociclib pre-treatment followed by tazemetostat/CPX-351combination.

Once the RDFE of tazemetostat in combination with CPX-351 and the RDFE of palbociclib pre-treatment followed by CPX-351 have been determined, we hope to pursue further evaluation of the safety and preliminary efficacy of the three-drug combination pending further protocol amendment..

After completion of study treatment, patients are followed up at 3 months, 6 months, and 1 year for clinical outcomes including survival.

03

Conditions studied

  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed and dated form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Male or female >= 18 years of age
  • confirmed acute myeloid leukemia (non-M3) from or refractory to at least 1 . Bone marrow aspirate and within 28 days of screening is acceptable. If no prior bone marrow biopsy is available, bone marrow biopsy must be performed during screening unless:

    * If the subject has >= 20% myeloblasts present in the peripheral blood, a bone marrow biopsy is not necessary to meet this criterion

  • Treatment with a prior agent is acceptable so long as it has not been administered within 2 weeks of enrollment and any prior adverse effects have resolved to grade 1 or less with the exception of alopecia
  • (ECOG) performance status of 2 or less
  • of at least 4 weeks
  • Must be able to consume oral medication
  • Subjects must have recovered from the toxic effect of any prior therapy to =\< grade 1 (except alopecia)
  • Creatine clearance (CrCL) >= 45
  • Total \< 2 x (ULN)
  • Female subjects of childbearing age must have a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Subjects with acute promyelocytic leukemia
  • Subjects receiving any active chemotherapy agents (except hydroxyurea). Intrathecal methotrexate and cytarabine are permissible
  • Subjects whose participation would result in a total cumulative dose of daunorubicin greater than 550 mg/m\^2 or greater than 450 mg/m\^2 if they previously received mediastinal radiation
  • Subjects with evidence of active central nervous system (CNS) leukemia involvement. Lumbar puncture is not required for enrollment in the absence of neurologic symptoms
  • Subjects must not be receiving growth factors (except erythropoietin)
  • Subjects with currently active second with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, resected prostate cancer with Gleason score =\< 6
  • Subjects with unstable cardiac disease or uncontrolled arrhythmia
  • Subjects with other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate to receive high-intensity therapy
  • Subjects who are pregnant or breastfeeding
  • Subjects with known allergic reactions to components of the study product(s)
  • Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part I (tazemetostat, CPX-351)

    Patients receive tazemetostat PO BID on days -1 to 6, and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.

    Drug: Tazemetostat · Drug: Liposome-encapsulated Daunorubicin-Cytarabine · Procedure: Bone Marrow Aspiration and Biopsy · Procedure: Biospecimen Collection

  • Experimental
    Part II: (Palbociclib Pre-Treatment Followed by CPX-351)

    Patients receive palbociclib PO QD on days -3 to -1 and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.

    Drug: Tazemetostat · Drug: Liposome-encapsulated Daunorubicin-Cytarabine · Procedure: Bone Marrow Aspiration and Biopsy · Procedure: Biospecimen Collection · Drug: Palbociclib

Interventions

  • Given PO

    Also known as: 1403254-99-8, E7438, EPZ-6438, EPZ6438, N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide, N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide

  • DrugCPX-351Studies of CPX-351CPX-351 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow aspiration and biopsy

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • Given PO

    Also known as: 571190-30-2, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-

06

What researchers measure

Primary outcomes

  1. Incidence of grade >= 3 non-hematologic dose limiting toxicities

    The primary outcome measure will be grade \>= 3 non-hematologic dose limiting toxicities. Adverse events will be coded by organ system and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0. the calculation of adverse events incidences will be passed on number of patients per adverse event category. Standard proportions will be used to report rates of safety endpoints. Summary tables will be presented by dose level, seriousness, severity and relatedness.

    Time frame: Up to 1 year

Secondary outcomes

  1. Incidence of adverse events

    Assessment of safety and tolerability: Incidence, nature, and severity of adverse events and incidence, nature and severity of treatment-emergent adverse events. The primary outcome measure will be grade \>= 3 non-hematologic dose limiting toxicities. Adverse events will be coded by organ system and graded according to the CTCAE v. 5.0. the calculation of adverse events incidences will be passed on number of patients per adverse event category. Standard proportions will be used to report rates of safety endpoints. Summary tables will be presented by dose level, seriousness, severity and relatedness.

    Time frame: Up to 1 year

  2. Complete response

    Morphologic leukemia-free state: \< 5% blasts in bone marrow, no blasts with Auer rods or persistence of extramedullary disease. Morphologic complete response (CR): \< 5% blasts in bone marrow with transfusion independence, absolute neutrophil count (ANC) \> 1.0 x 10\^9/L, platelets \>= 100 x10\^9/L. CR without minimal residual disease: morphologic CR with negative molecular markers by real-time quantitative polymerase chain reaction or negative multi-parameter flow cytometry. CR with partial hematologic recovery (CRh): as \< 5% blasts in bone marrow with no evidence of disease and partial recovery of peripheral blood counts (ANC \> 0.5 x 10\^9/L and platelets \> 50 x 10\^9/L). CR with incomplete hematologic recovery (CRi): all CR criteria and transfusion independence but with persistence of neutropenia (ANC \< 1.0 x 10\^9/L) or thrombocytopenia (platelets \< 100 x 10\^9/L). Composite complete response: CR + CRh + CRi.

    Time frame: Up to 1 year

  3. Partial remission (PR)

    PR is defined as decrease of at least 50% in the percentage of bone marrow blasts to 5% - 25% and normalization of blood counts.

    Time frame: Up to 1 year

  4. Relapse

    Relapse is defined as reappearance of leukemic blasts in the peripheral blood or \> 5% blasts in the bone marrow not attributable to other cause (e.g., bone marrow regeneration after chemotherapy) or extramedullary relapse.

    Time frame: Up to 1 year

  5. Induction failure/refractory acute myeloid leukemia (AML)

    Induction failure/refractory AML defined as failure to attain CR or CRi.

    Time frame: Up to 1 year

  6. Time to blood count recovery

    95% confidence intervals will be calculated using Kaplan-Meier method.

    Time frame: The number of days until ANC > 1.0 x 10^9/L and platelets >= 100 x 10^9/L from day 1 of treatment, assessed up to 1 year

  7. Relapse free survival

    95% confidence intervals will be calculated using Kaplan-Meier method.

    Time frame: The time measured in months to relapse from day 1 of treatment, assessed up to 1 year

  8. Overall survival

    95% confidence intervals will be calculated using Kaplan-Meier method.

    Time frame: The time measured in months from day 1 of treatment, assessed up to 1 year

  9. Rate of allogeneic stem cell transplantation

    Defined as the proportion of patients who undergo allogeneic stem cell transplantation during the study period.

    Time frame: Up to 1 year

  10. Time to transplant

    95% confidence intervals will be calculated using Kaplan-Meier method.

    Time frame: The time measured in months to allogeneic stem cell transplantation from day 1 of treatment, assessed up to 1 year

Other outcomes

  1. Deoxyribonucleic acid (DNA) damage and apoptosis

    DNA damage (analysis of gammaH2AX-positive AML cells by confocal microscopy) and apoptosis (Annexin V and caspase 3 activation) will be assessed in S phase-enriched AML cells (16-24 hours post palbociclib treatment) following treatment with the EZH2 inhibitor tazemetostat to de-condense the H3K27me3-marked chromatin and chemotherapy (CPX-351) to induce DNA damage (double strand breaks).

    Time frame: Up to day 5

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2028, 53 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 53 months is close to that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 25, 2022
StartActual
Aug 28, 2023
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05627232
Collaborators
Pennsylvania Department of Health
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Aug 28, 2023
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Gina Keiffer, MD
Contact
gina.keiffer@jefferson.edu
215-955-2929
Gina Keiffer, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tazemetostat · CPX-351 · Palbociclib

Start the discussion